OncoMatch/Clinical Trials/NCT02393157
Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL
Is NCT02393157 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments for non-hodgkin lymphoma.
Treatment: Obinutuzumab · Liposomal ARA-C · Ifosfamide · Carboplatin · Etoposide — The purpose of this study is to determine the safety of administering obinutuzumab as a single agent alone and in combination with ifosfamide, carboplatin, and etoposide (ICE) chemotherapy and determine the response rate of this treatment for children, adolescents and young adults (CAYA) with relapsed CD20 positive B-cell Non-Hodgkin Lymphoma (B-NHL).
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Diffuse Large B-Cell Lymphoma
Acute Lymphoblastic Leukemia
Biomarker criteria
Required: MS4A1 positive (CD20 positive)
CD20 positive B-cell leukemia/lymphoma
Prior therapy
Cannot have received: obinutuzumab (obinutuzumab)
Patients may not have received prior therapy with obinutuzumab (GA101)
Cannot have received: myelosuppressive chemotherapy
Exception: Must not have received within 2 weeks of entry onto this study
Myelosuppressive chemotherapy: Must not have received within 2 weeks of entry onto this study.
Cannot have received: radiation therapy
Exception: Date of receiving prior XRT must be > 2 weeks for local palliative XRT (small port); > 6 months must have elapsed if prior craniospinal XRT or if > 50% radiation of pelvis; > 6 weeks must have elapsed if other substantial bone marrow radiation.
Radiation Therapy (XRT): Date of receiving prior XRT must be > 2 weeks for local palliative XRT (small port); > 6 months must have elapsed if prior craniospinal XRT or if > 50% radiation of pelvis; > 6 weeks must have elapsed if other substantial bone marrow radiation.
Cannot have received: allogeneic stem cell transplant
Exception: within 60 days or active acute GVHD grade 3 or higher
Prior allogeneic stem cell transplant within 60 days or active acute Graft-vs-Host-Disease (GVHD) grade 3 or higher.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- New York Medical College · Valhalla, New York
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify